About AC BioScience
AC BioScience is a start-up biotech company with an innovative vision and business model. We are dedicated to developing new therapies to fight a range of cancers.
Founded by Andreas Schläpfer and Professor Christian Auclair, the company is leading a paradigm shift in cancer therapeutics. AC BioScience is headquartered at the EPFL Innovation Park near Lausanne, and celebrated its second year of existence in March 2019.
Our primary focus is on developing personalized therapies for tumoral pathologies. We have obtained patent protection for one ground-breaking cancer therapy and have filed patents for two others.
Advertisement
Product portfolio of AC BioScience
Here you will find AC BioScience SA
Last viewed contents
The spider with the bee venom - New perspectives for the search for active substances against cell-based diseases - Researchers decode the toxin arsenal of the most poisonous native spider species
Spirea Ltd - Harrogate, United Kingdom
LETI Pharma GmbH - Ismaning, Germany
Opening the door to affordable lab-grown beef, cow cells defy aging - A potential game-changer for creating sustainable, ethical meat without the environmental toll of traditional livestock farming
EMD Serono, Inc. - Rockland, USA
Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”
Being fit Protects Against Health Risks Caused by Stress at Work
WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership
F-star - Wien, Austria
Chemical pollution threatens biodiversity - Scientists say more environmental pollutants should be considered in species protection
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government - Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency